No profile data available.
Ardelyx, Inc. (ARDX) is a healthcare company in the blood disorder treatment drugs industry, based in Waltham, United States, with about 489 full-time employees.
It reported revenue of $407.32 million for fiscal year 2025, up 22.1% from fiscal year 2024, and net income of -$61.60 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $120.88 million, up 23.8% from a year before. United States was its largest region in fiscal year 2025, with 93% of revenue. Its market capitalization was $846.86 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Ardelyx reported $407.32 million in revenue for fiscal year 2025, up 22.1% from $333.62 million in fiscal year 2024. In Q2 2026 revenue was $120.88 million.
United States: 93% of revenue by region in fiscal year 2025, followed by Asia Pacific (7%).
$846.86 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood disorder treatment drugs) include Agios Pharmaceuticals, Inc. (AGIO), uniQure N.v. (QURE), Ultragenyx Pharmaceutical Inc. (RARE), Geron Corporation (GERN).